Implementation of polygenic risk score guided breast cancer precision prevention

The project has been supported by the Norway Grants Green ICT programme.

Project AnteNOR

Project implementation period: 01.07.2021-30.04.2024
Grant amount: 761 360,20 €
Total budget: 1 523 025 €

Antegenes has registered and CE-certified a breast cancer genetic risk test AnteBC that is based on polygenic risk scores technology. AnteBC allows to differentiate women’s genetic predisposition to breast cancer and to make more specific recommendations for the prevention and early detection of breast cancer.

Project’s goal

The general objective of the project is to implement AnteBC test as part of a breast cancer screening routine in Norway. Current breast cancer screening is only age based but can decrease mortality by around 20% if invitations account for AnteBC results. The project activities deploy AnteBC to Norwegian healthcare: a consortium of partners assesses the test performance in the Norwegian population, conducts a clinical pilot study and assembles technical documentation to prepare for public reimbursement.

 

Project result

By the end of the project, the performance of the AnteBC test based on the genetic data of the Norwegian population has been analyzed, a successful clinical trial has been conducted in Norwegian clinical settings and the necessary scientific and regulatory documentation has been developed for the implementation of breast cancer precision prevention. Also, necessary trainings for healthcare professionals have been conducted.

 

About us

Antegenes is an Estonian health technology company and medical laboratory with a goal to develop and implement advanced genetic tests based on polygenic risk scores technology for the prevention of major complex diseases.

 

Project main progress

July – December 2021

  • AnteNOR project kick-off
  • Green ICT project was mentioned in Delfi Ärileht article
  • Mapped and interviewed Norwegian key stakeholders in the field of breast cancer and breast cancer mammography screening
  • Applied and received the ethical commitee approval for genetic analysis study
  • Analysis of Norwegian genetic data started
  • Antegenes became a member of Oslo Cancer Cluster
  • Presentation about Antegenes and AnteNOR project at Oslo Cancer Cluster virtual annual meeting on 15th of December

January – June 2022

  • Started cooperation with Oecona AS
  • Participated in EXPO 2020 Dubai for international scientific cooperations
  • Green ICT project was mentioned in e-Estonia blog article.
  • Development of the cost-benefit simulation study for Norwegian medical setting
  • AnteNOR seminar was organized in Oslo by Oslo Cancer Cluster and Antegenes
  • AnteNOR project clinical pilot study protocol created and ready
  • Application for conducting the AnteNOR clinical pilot is submitted to Regional Ethical Commitee

Project contact

OÜ Antegenes
Dr Peeter Padrik
peeter.padrik@antegenes.com